Alnylam's New Therapy Reduces Cardiovascular Event Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ALNY?
Source: Newsfilter
- Sustained Efficacy: The HELIOS-B study demonstrated that vutrisiran significantly reduced all-cause mortality and cardiovascular events in ATTR-CM patients, particularly in the 65% of patients with atrial fibrillation, highlighting its potential as a first-line treatment option.
- Safety Analysis: A pooled analysis of over 25,000 patient-years indicated that the rates of vitamin A deficiency-related ocular adverse events were low and comparable to placebo, reinforcing confidence in the safety profile of vutrisiran for clinical use.
- Long-Term Study Design: The DemonsTTRate study aims to enroll over 2,000 ATTR-CM patients to generate up to five years of real-world clinical outcome data, further validating the clinical effectiveness and treatment patterns of vutrisiran.
- Global Experience Accumulation: Vutrisiran has accumulated over 13,000 patient-years of global experience in both ATTR-CM and hereditary transthyretin-mediated amyloidosis (hATTR-PN), reflecting its efficacy and safety across diverse patient populations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 295.050
Low
351.00
Averages
479.53
High
580.00
Current: 295.050
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alnylam's New Therapy Reduces Cardiovascular Event Risks
- Sustained Efficacy: The HELIOS-B study demonstrated that vutrisiran significantly reduced all-cause mortality and cardiovascular events in ATTR-CM patients, particularly in the 65% of patients with atrial fibrillation, highlighting its potential as a first-line treatment option.
- Safety Analysis: A pooled analysis of over 25,000 patient-years indicated that the rates of vitamin A deficiency-related ocular adverse events were low and comparable to placebo, reinforcing confidence in the safety profile of vutrisiran for clinical use.
- Long-Term Study Design: The DemonsTTRate study aims to enroll over 2,000 ATTR-CM patients to generate up to five years of real-world clinical outcome data, further validating the clinical effectiveness and treatment patterns of vutrisiran.
- Global Experience Accumulation: Vutrisiran has accumulated over 13,000 patient-years of global experience in both ATTR-CM and hereditary transthyretin-mediated amyloidosis (hATTR-PN), reflecting its efficacy and safety across diverse patient populations.
See More
Alnylam to Present New Vutrisiran Data at Heart Failure 2026
- New Data Presentation: Alnylam Pharmaceuticals will present new data analyses for vutrisiran at the Heart Failure 2026 congress in Barcelona from May 9-12, 2026, further supporting its efficacy as a first-line treatment for patients with cardiomyopathy.
- Clinical Study Validation: The HELIOS-B study demonstrates vutrisiran's adaptability to patients with high disease burden, indicating its potential value in complex clinical scenarios, which may enhance treatment options for patients.
- Global Observational Study: Alnylam will also introduce the design of the DemonsTTRate study, aimed at evaluating the real-world use of vutrisiran, emphasizing the company's commitment to long-term efficacy and potentially providing critical data for future clinical practices.
- Safety Analysis: The congress will showcase a safety analysis of vutrisiran related to vitamin A, assessing adverse reactions in clinical trials and real-world datasets, ensuring patient safety and treatment effectiveness during administration.
See More
Alnylam Pharmaceuticals Q1 Results Exceed Expectations
- Performance Beat: Alnylam Pharmaceuticals reported Q1 revenue of $1.2 billion, exceeding forecasts by 4.5%, with earnings per share (EPS) at $1.51, 67% above expectations, indicating strong financial performance that boosts investor confidence.
- Future Growth Outlook: Analysts forecast revenues of $5.61 billion in 2026, reflecting a 31% increase from the past 12 months, with EPS expected to soar 86% to $7.51, showcasing a more bullish sentiment towards the company's earnings potential.
- Stable Price Target: Despite the improved earnings outlook, the consensus price target remains unchanged at $449, suggesting that the market does not anticipate significant long-term value creation, prompting investors to consider diverse valuation opinions.
- Industry Growth Comparison: Alnylam is projected to achieve an annualized growth rate of 43% by 2026, significantly outpacing the 21% growth forecast for similar companies, highlighting its competitive advantage and market potential in the biopharmaceutical sector.
See More
Alnylam Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Alnylam reported over $1 billion in global net product revenues for Q1 2026, with TTR revenue reaching $910 million, indicating strong performance in the TTR market and supporting the achievement of the annual sales guidance of $4.4 billion to $4.7 billion.
- Strategic Collaboration Expansion: CEO Yvonne Greenstreet highlighted new partnerships aimed at enhancing TTR disease awareness and diagnosis, reflecting Alnylam's pursuit of global leadership under its 'Alnylam 2030' strategy, which focuses on sustainable innovation for business growth.
- Increased R&D Spending: CFO Jeffrey Poulton reported non-GAAP R&D expenses of $335 million, a 39% increase, indicating ongoing investment in research and development, while maintaining profitability, showcasing confidence in future product development.
- Market Dynamics Analysis: Management emphasized that despite challenges from German pricing adjustments and U.S. insurance reauthorizations, Q1 results were consistent with expectations, demonstrating the company's flexibility and adaptability in navigating market fluctuations.
See More
Alnylam Pharmaceuticals Q1 Earnings Exceed Expectations
- Strong Earnings Report: Alnylam Pharmaceuticals reported a Q1 non-GAAP EPS of $1.99, beating expectations by $0.52, which highlights the company's improved profitability and boosts investor confidence.
- Revenue Surge: The company achieved Q1 revenue of $1.17 billion, representing a 96.9% year-over-year increase and exceeding market expectations by $50 million, reflecting robust demand and sales performance for its products.
- Guidance Reaffirmation: Alnylam reiterated its 2026 financial guidance, projecting combined net product revenues between $4.9 billion and $5.3 billion, and total TTR net product revenues between $4.4 billion and $4.7 billion, indicating strong confidence in future growth.
- Market Strategy: Alnylam has made progress in transforming ATTR amyloidosis care and expanding its TTR franchise, demonstrating its strategic decision-making capabilities in innovative drug development and market expansion.
See More
Alnylam Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Alnylam Pharmaceuticals is set to announce its Q1 2023 earnings on April 30 before market open, with consensus EPS estimate at $0.91 and revenue expected to reach $1.12 billion, reflecting an impressive 88.5% year-over-year growth, marking a critical performance indicator for the company.
- Performance Expectations: Over the past two years, Alnylam has beaten EPS and revenue estimates 63% of the time, indicating stability in managing market expectations, although recent revisions show 7 downward adjustments for EPS and 12 for revenue in the last three months.
- Market Reaction: Despite the optimistic outlook, analysts caution that Alnylam's current valuation may still appear overvalued, urging investors to carefully assess the balance between long-term growth potential and short-term performance volatility.
- Strategic Partnership Progress: Alnylam's research pact with Tenaya, valued at up to $1.1 billion, underscores the company's ongoing innovation in treating ATTR amyloidosis and its strategy to expand the TTR franchise, potentially supporting future revenue growth.
See More
Alnylam's New Therapy Reduces Cardiovascular Event Risks
- Sustained Efficacy: The HELIOS-B study demonstrated that vutrisiran significantly reduced all-cause mortality and cardiovascular events in ATTR-CM patients, particularly in the 65% of patients with atrial fibrillation, highlighting its potential as a first-line treatment option.
- Safety Analysis: A pooled analysis of over 25,000 patient-years indicated that the rates of vitamin A deficiency-related ocular adverse events were low and comparable to placebo, reinforcing confidence in the safety profile of vutrisiran for clinical use.
- Long-Term Study Design: The DemonsTTRate study aims to enroll over 2,000 ATTR-CM patients to generate up to five years of real-world clinical outcome data, further validating the clinical effectiveness and treatment patterns of vutrisiran.
- Global Experience Accumulation: Vutrisiran has accumulated over 13,000 patient-years of global experience in both ATTR-CM and hereditary transthyretin-mediated amyloidosis (hATTR-PN), reflecting its efficacy and safety across diverse patient populations.
See More
Alnylam to Present New Vutrisiran Data at Heart Failure 2026
- New Data Presentation: Alnylam Pharmaceuticals will present new data analyses for vutrisiran at the Heart Failure 2026 congress in Barcelona from May 9-12, 2026, further supporting its efficacy as a first-line treatment for patients with cardiomyopathy.
- Clinical Study Validation: The HELIOS-B study demonstrates vutrisiran's adaptability to patients with high disease burden, indicating its potential value in complex clinical scenarios, which may enhance treatment options for patients.
- Global Observational Study: Alnylam will also introduce the design of the DemonsTTRate study, aimed at evaluating the real-world use of vutrisiran, emphasizing the company's commitment to long-term efficacy and potentially providing critical data for future clinical practices.
- Safety Analysis: The congress will showcase a safety analysis of vutrisiran related to vitamin A, assessing adverse reactions in clinical trials and real-world datasets, ensuring patient safety and treatment effectiveness during administration.
See More
Alnylam Pharmaceuticals Q1 Results Exceed Expectations
- Performance Beat: Alnylam Pharmaceuticals reported Q1 revenue of $1.2 billion, exceeding forecasts by 4.5%, with earnings per share (EPS) at $1.51, 67% above expectations, indicating strong financial performance that boosts investor confidence.
- Future Growth Outlook: Analysts forecast revenues of $5.61 billion in 2026, reflecting a 31% increase from the past 12 months, with EPS expected to soar 86% to $7.51, showcasing a more bullish sentiment towards the company's earnings potential.
- Stable Price Target: Despite the improved earnings outlook, the consensus price target remains unchanged at $449, suggesting that the market does not anticipate significant long-term value creation, prompting investors to consider diverse valuation opinions.
- Industry Growth Comparison: Alnylam is projected to achieve an annualized growth rate of 43% by 2026, significantly outpacing the 21% growth forecast for similar companies, highlighting its competitive advantage and market potential in the biopharmaceutical sector.
See More
Alnylam Pharmaceuticals Q1 2026 Earnings Call Highlights
- Significant Revenue Growth: Alnylam reported over $1 billion in global net product revenues for Q1 2026, with TTR revenue reaching $910 million, indicating strong performance in the TTR market and supporting the achievement of the annual sales guidance of $4.4 billion to $4.7 billion.
- Strategic Collaboration Expansion: CEO Yvonne Greenstreet highlighted new partnerships aimed at enhancing TTR disease awareness and diagnosis, reflecting Alnylam's pursuit of global leadership under its 'Alnylam 2030' strategy, which focuses on sustainable innovation for business growth.
- Increased R&D Spending: CFO Jeffrey Poulton reported non-GAAP R&D expenses of $335 million, a 39% increase, indicating ongoing investment in research and development, while maintaining profitability, showcasing confidence in future product development.
- Market Dynamics Analysis: Management emphasized that despite challenges from German pricing adjustments and U.S. insurance reauthorizations, Q1 results were consistent with expectations, demonstrating the company's flexibility and adaptability in navigating market fluctuations.
See More
Alnylam Pharmaceuticals Q1 Earnings Exceed Expectations
- Strong Earnings Report: Alnylam Pharmaceuticals reported a Q1 non-GAAP EPS of $1.99, beating expectations by $0.52, which highlights the company's improved profitability and boosts investor confidence.
- Revenue Surge: The company achieved Q1 revenue of $1.17 billion, representing a 96.9% year-over-year increase and exceeding market expectations by $50 million, reflecting robust demand and sales performance for its products.
- Guidance Reaffirmation: Alnylam reiterated its 2026 financial guidance, projecting combined net product revenues between $4.9 billion and $5.3 billion, and total TTR net product revenues between $4.4 billion and $4.7 billion, indicating strong confidence in future growth.
- Market Strategy: Alnylam has made progress in transforming ATTR amyloidosis care and expanding its TTR franchise, demonstrating its strategic decision-making capabilities in innovative drug development and market expansion.
See More
Alnylam Pharmaceuticals Q1 Earnings Announcement Scheduled
- Earnings Release Date: Alnylam Pharmaceuticals is set to announce its Q1 2023 earnings on April 30 before market open, with consensus EPS estimate at $0.91 and revenue expected to reach $1.12 billion, reflecting an impressive 88.5% year-over-year growth, marking a critical performance indicator for the company.
- Performance Expectations: Over the past two years, Alnylam has beaten EPS and revenue estimates 63% of the time, indicating stability in managing market expectations, although recent revisions show 7 downward adjustments for EPS and 12 for revenue in the last three months.
- Market Reaction: Despite the optimistic outlook, analysts caution that Alnylam's current valuation may still appear overvalued, urging investors to carefully assess the balance between long-term growth potential and short-term performance volatility.
- Strategic Partnership Progress: Alnylam's research pact with Tenaya, valued at up to $1.1 billion, underscores the company's ongoing innovation in treating ATTR amyloidosis and its strategy to expand the TTR franchise, potentially supporting future revenue growth.
See More
